EP2627319B1 - Compositions pharmaceutiques contenant un inhibiteur dgat1 - Google Patents

Compositions pharmaceutiques contenant un inhibiteur dgat1 Download PDF

Info

Publication number
EP2627319B1
EP2627319B1 EP11779278.8A EP11779278A EP2627319B1 EP 2627319 B1 EP2627319 B1 EP 2627319B1 EP 11779278 A EP11779278 A EP 11779278A EP 2627319 B1 EP2627319 B1 EP 2627319B1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
pharmaceutical composition
tablet
film coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP11779278.8A
Other languages
German (de)
English (en)
Other versions
EP2627319A1 (fr
Inventor
Hong Wen
Natrajan Kumaraperumal
Richard Nause
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44908106&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2627319(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to PL11779278T priority Critical patent/PL2627319T3/pl
Priority to SI201131677T priority patent/SI2627319T1/sl
Publication of EP2627319A1 publication Critical patent/EP2627319A1/fr
Application granted granted Critical
Publication of EP2627319B1 publication Critical patent/EP2627319B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to pharmaceutical compositions comprising (4- ⁇ 4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl ⁇ -cyclohexyl)-acetic acid, or a pharmaceutically acceptable salt thereof, e.g. the sodium salt thereof, as the active ingredient in a suitable carrier.
  • the present invention also relates to the processes for their preparation and to their use as medicaments.
  • a genus of compounds as DGAT1-inhibitors including, as Example 5-1, the compound (4- ⁇ 4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl ⁇ -cyclohexyl)-acetic acid, having the structural formula (I): and its sodium salt may be employed in the treatment of a condition or a disorder such as inflammatory conditions, obesity, diabetes and related metabolic disorders.
  • parenteral administration is preferred to parenteral administration because it allows self-administration by patients whereas parenteral formulations have to be administered in most cases by a physician or paramedical personnel. It is also important that dosage units which are manufactured and given to a patient have a high degree of uniformity in the amount of drug substance among the individual dosage units. In addition, the formulation must have a good dissolution profile and an optimal in-vivo drug-release profile with minimal unit-to-unit variability.
  • WO 2007/126957 mentions that the compounds disclosed in this document may be employed in the manufacture of pharmaceutical compositions, preferably tablets containing several excipients such as surfactants with lubricant properties, dry binders with disintegrant properties, fillers or disintegrants, as well as lubricants.
  • WO 2007/126957 does not disclose any particular pharmaceutical composition, especially not of the sodium salt of the compound (4- ⁇ 4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl ⁇ -cyclohexyl)-acetic acid, and instead remains completely generic in this respect.
  • WO 2011/123401 discloses tablet formulations of the sodium salt of the compound (4- ⁇ 4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl ⁇ -cyclohexyl)-acetic acid, which however do not solve the particular problems of said compound:
  • the compound of formula (I), or a pharmaceutically acceptable salt thereof, in particular the sodium salt thereof, is a drug substance which is difficult to formulate due to its physicochemical properties.
  • the sodium salt of the compound of formula (I), depicted above as the compound of formula (II) is hygroscopic, poorly soluble and highly permeable, with a high moisture uptake at 95% relative humidity. It is also plate like, very fluffy, and sticky in nature. It also exhibits poor flow characteristics.
  • Example 1 The formulations of Example 1, for instance, as disclosed in WO 2011/123401 , were very sensitive to process parameters. It was found that compression at different hardnesses led to very different dissolution profiles. It was thus necessary to reduce the tablet to tablet variability of the drug release of the formulation, as this would have a major impact on the in-vivo availability of the drug. It was also necessary to develop a formulation which would be more robust to pocess parameters, and which would avoid one of the major problems associated with the compound of formula (II), i.e. its stickiness.
  • the invention thus provides a pharmaceutical composition in the form of a tablet with optional film coating comprising
  • Such formulation exhibits one or more, e.g. 1, 2 or 3, of the following desirable characteristics;
  • the formulations of the present invention are also achievable via a robust manufacturing process; which gives good flowability, compactibility, and which minimizes sticking problems and capping of tabletting mixtures on the rotary press.
  • the process and the formulations are amenable to scale-up, with a reproducible performance.
  • the pharmaceutical composition in accordance with the present invention is, as defined in claim 1.
  • the use of the specificied excipients surprisingly overcomes the problems of formulating the compound of formula (I), or a pharmaceutically acceptable salt, in particular the sodium salt of formula (II), into a solid oral dosage form.
  • the present invention provides a composition which shows good physical and chemical stability during storage, which has a good dissolution profile, which is not sensitive to manufacturing parameters, and in which the unit to unit variation in drug release is minimized.
  • the present invention also provides a process which enables maximum drug load to be achieved and which is not sensitive to manufacturing parameters.
  • compositions of the present invention contain sodium lauryl sulfate (SLS) as surfactant with lubricant properties, wherein said surfactant is present in an amount which is 0.1 to 5% by weight of the tablet prior to any optional film coating and based on the free acid of the compound of the formula (I).
  • SLS sodium lauryl sulfate
  • the surfactant or combination of surfactants may be employed in an amount ranging from about 0.1% to about 5%, preferably from about 0.5% to about 3%, e.g. 2%, by weight of the tablet (prior to any optional film coating). These percentages are based on the compound of the formula (I) and if a salt is used the percentages will be adapted accordingly.
  • compositions of the present invention in addition contain hydroxypropylmethyl cellulose or hydroxypropyl cellulose, both of medium to high viscosity, and combinations thereof as dry binder, wherein said dry binder is present in an amount which is 2 to 20% by weight of the tablet prior to any optional film coating and based on the free acid of the compound of the formula (I);.
  • the dry binders to be employed in accordance in the present invention include hydroxypropylmethyl cellulose or hydroxypropyl cellulose, both preferably of medium to high viscosity, e.g., viscosity grades 3 or 6 cps, e.g.low substituted hydroxypropyl cellulose (L-HPC LH-21); and combinations thereof.
  • a most preferred binder is low substituted hydroxypropyl cellulose (L-HPC LH-21).
  • the dry binder or or combination of dry binders may be employed in an amount ranging from about 2% to about 20%, preferably from about 5% to about 15%, e.g. about 10% by weight of the tablet (prior to any optional film coating). These percentages are based on the compound of the formula (I) and if a salt is used the percentages will be adapted accordingly.
  • the fillers to be employed in accordance in the present invention include microcrystalline cellulose (e.g., cellulose MK GR and products available under the registered trade marks AVICEL, FILTRAK, HEWETEN or PHARMACEL, Vivapur, emcocel, tabulose), Anhydrous Dicalcium Phosphate, Anhydrous Lactose , and combinations thereof, and a combination of microcrystalline cellulose and Anhydrous Dicalcium Phosphate, and a combination of microcrystalline cellulose and lactose, and wherein said filler is present in an amount which is 4% to 85%.
  • microcrystalline cellulose e.g., cellulose MK GR and products available under the registered trade marks AVICEL, FILTRAK, HEWETEN or PHARMACEL, Vivapur, emcocel, tabulose
  • Anhydrous Dicalcium Phosphate Anhydrous Lactose
  • combinations thereof a combination of microcrystalline cellulose and Anhydrous Dicalcium P
  • the filler is microcrystalline cellulose, Anhydrous Dicalcium Phosphate and Anhydrous Lactose , or a mixture thereof.
  • Combination of fillers may be used such as combinations of microcrystalline cellulose and Anhydrous Dicalcium Phosphate, and combinations of microcrystalline cellulose and lactose.
  • the filler or combination of fillers may be employed in an amount ranging from about 4% to about 85%, preferably from about 20% to about 85%, most preferably from about 50-80%, e.g, 50-65% or 70-80% by weight of the tablet (prior to any optional film coating). These percentages are based on the compound of the formula (I) and if a salt is used the percentages will be adapted accordingly.
  • fillers When combinations of fillers are used, they may be used in a ratio of from 1:1 to 1:5, preferably 1:2 ratio.
  • the filler is a combination of microcrystalline cellulose and another filler, e.g. Anhydrous Dicalcium Phosphate, or lactose, wherein the ratio of the microcrystalline cellulose to lactose, or of microcrystalline cellulose to anhydrous dicalcium phosphate is 1:2.
  • disintegrants to be employed in the pharmaceutical compositions of the present invention can be extragranular or intragranular, or both.
  • examples of disintegrants to be employed in accordance in the present invention include Sodium Starch Glycollate (SSG) wherein said disintegrant is present in an amount which is 1 to 10% by weight of the tablet prior to any optional film coating and based on the free acid of the compound of the formula (I).
  • SSG Sodium Starch Glycollate
  • the disintegrant or combination of disintegrants may be employed in an amount ranging from about 1% to about 10%, most preferably from about 1% to about 6%, by weight of the tablet (prior to any optional film coating). In one embodiment, the disintegrant is present in an amount which is 2, 6 or 9% by weight of the tablet. These percentages are based on the compound of the formula (I) and if a salt is used the percentages will be adapted accordingly.
  • Lubricants may provide advantages in the formulation of a pharmaceutical composition when the drug substance is poorly water soluble and a compaction process, such as a roller compaction process, is used with drug loads as high as 25% w/w.
  • the pharmaceutical compositions of the present invention may in addition contain one or more, e.g. 1, 2 or 3, lubricants.
  • the lubricants to be employed in accordance in the present invention include, without limitation, magnesium stearate, aluminum or calcium silicate, stearic acid, cutina, PEG 4000-8000, talc and combinations thereof, preferably Sodium Stearyl Fumarate or magnesium stearate, more preferably Sodium Stearyl Fumarate.
  • the lubricant or lubricants may be employed in an amount ranging from about 0.1% to about 10%, preferably from about 0.5% to about 5%, e.g. 2-3%, by weight of the tablet (prior to any optional film coating). These percentages are based on the compound of the formula (I) and if a salt is used the percentages will be adapted accordingly.
  • the compound of formula (I), or a pharmaceutically acceptable salt may be employed in an amount ranging from about 0.1% to about 50%, preferably from about 0.5% to about 30%, most preferably from about 1-30%, by weight of the pharmaceutical compositions (prior to any optional film coating).
  • the compound of formula (I) may be present in 2, 10, 15, 20, 25 and 30 % by weight of the pharmaceutical compositions. These percentages are based on the compound of the formula (I) and if a salt is used the percentages will be adapted accordingly.
  • the amount of each additive in a pharmaceutical oral fixed dose combination may vary within ranges conventional in the art.
  • Suitable glidants include, without limitation, colloidal silicon dioxide (e.g., Aerosil 200), magnesium trisilicate, powdered cellulose, starch, talc and combinations thereof.
  • a glidant or glidants in the layer containing component a) may be employed in an amount ranging from about 00.05% to about 5%, preferably from about 0.1% to about 1%, more preferably from about 0.25% to about 1%., e.g. 0.25 or 0.5%, by weight of the tablet (prior to any optional film coating). These percentages are based on the compound of the formula (I) and if a salt is used the percentages will be adapted accordingly.
  • the invention provides a pharmacceutical composition, as described in claim 1.
  • compositions provided herein may contain in addition, lubricants, glidants, colorants, and combinations thereof, as detailed above.
  • the amounts of each of the excipients, and the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, are as described herein, and as described in the Examples.
  • the hardness is measured by standard methods known to the person skilled in the art, see the harmonized procedure set forth in the pharmacopeias USP ⁇ 1217> and EP 2.9.8 and JP. If the tablet is too soft, it will not withstand handling during the subsequent processing, such as coating or packaging and shipping operations. Likewise, if the tablet is too hard, it may not disintegrate in the required period of time or meet the dissolution specification.
  • a general principle for hardness testing is that the larger the tablet, the higher the hardness. It is thus a goal of the formulator to improve the compression / hardness profile so as to minimize the influence of hardness on disintegration time and dissolution, and to maximize the drug load.
  • Release profile refers to a process by which the pharmaceutical oral fixed dose combination is brought into contact with a fluid and the fluid transports the drug(s) outside the dosage form into the fluid that surrounds the dosage form.
  • the combination of delivery rate and delivery duration exhibited by a given dosage form in a patient can be described as its in vivo release profile.
  • the release/dissolution profiles of dosage forms may exhibit different rates and durations of release and may be continuous.
  • Continuous release profiles include release profiles in which one or more, e.g. 1, 2 or 3, active ingredients are released continuously, either at a constant or variable rate.
  • An adequate drug release profile for the pharmaceutical composition may be e.g. 80% within 45 minutes.
  • Disintegration refers to a process where the pharmaceutical oral fixed dose combination, typically by means of a fluid, falls apart into separate particles and is dispersed. Disintegration is achieved when the solid oral dosage form is in a state in which any residue of the solid oral dosage form, except fragments of insoluble coating or capsule shell, if present, remaining on the screen of the test apparatus is a soft mass having no palpably firm core in accordance with USP ⁇ 701>.
  • the fluid for determining the disintegration property is water, such as tap water or deionized water.
  • the disintegration time is measured by standard methods known to the person skilled in the art, see the harmonized procedure set forth in the pharmacopeias USP ⁇ 701> and EP 2.9.1 and JP.
  • Dissolution rate refers to a process by which a solid substance, here the active ingredients, is dispersed in molecular form in a medium.
  • the dissolution rate of the active ingredients of the pharmaceutical oral fixed dose combination of the invention is defined by the amount of drug substance that goes in solution per unit time under standardized conditions of liquid/solid interface, temperature and solvent composition.
  • the dissolution rate is measured by standard methods known to the person skilled in the art, see the harmonized procedure set forth in the pharmacopeias USP ⁇ 711> and EP 2.9.3 and JP.
  • the test is for measuring the dissolution of the individual active ingredients is performed following pharmacopeia USP ⁇ 711> at pH 4.5 using a paddle stirring element at 75 rpm (rotations per minute).
  • the dissolution medium is preferably a buffer, typically a phosphate buffer, especially one as described in the example "Dissolution Test".
  • the molarity of the buffer is preferably 0.1 M.
  • An adequate dissolution profile for a slowly dissolving or poorly water soluble drug may mean for example, more than 80%, e.g. 85%, dissolution within 30, 45, or 60 minutes, see e.g. Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms, Aug 1997, p. 5 .
  • particulate refers to a state of matter which is characterized by the presence of discrete particles, pellets, beads or granules irrespective of their size, shape or morphology. When a plurality of particulates is present, these are referred to as multiparticulates. Typically, the particulates have an average size of lower than about 3 mm, preferably between about 1 ⁇ m to 3 mm. By “average particle size” it is meant that at least 50% of the particulates have a particle size of less than about the given value, by weight. The particle size may be determined on the basis of the weight average particle size as measured by conventional particle size measuring techniques well known to those skilled in the art. Such techniques include, for example, sedimentation field flow fractionation, photon correlation spectroscopy, light scattering, and disk centrifugation.
  • effective amount refers to the amount of the active ingredient or agent which halts or reduces the progress of the condition being treated or which otherwise completely or partly cures or acts palliatively on the condition.
  • prophylactically effective amount refers to the amount of the active ingredient or agent prevents the onset of the disease, condition or disorder.
  • warm-blooded animal or patient are used interchangeably herein and include, but are not limited to, humans, dogs, cats, horses, pigs, cows, monkeys, rabbits, mice and laboratory animals. In one embodiment, the mammals are humans.
  • treatment means the management and care of a patient for the purpose of preventing, combating or delaying progression of the disease, condition or disorder, preferably for the purpose of combating the disease, condition or disorder, and in particular it also prophylactic treatment.
  • prevention /"preventing are to be understood as meaning the prophylactic administration of a drug, such as a combined preparation or pharmaceutical composition, to healthy patients to prevent the outbreak of the disease, condition or disorder.
  • drug active substance
  • active ingredient active agent
  • the present invention overcomes the drawbacks associated with formulating the drug substance and providies a specific process for preparing a pharmaceutical composition comprising the compound of the formula (I), or a pharmaceutically acceptable salt thereof.
  • the invention provides in another of its aspects a process of making a solid oral dosage form as hereinabove described.
  • a solid oral dosage form may be produced by working up the final composition defined hereinabove in appropriate amounts, to form unit dosage forms.
  • a process for preparing a pharmaceutical composition comprising the steps of mixing compound of formula (I), or a pharmaceutically acceptable salt thereof, with at least one pharmaceutically acceptable excipient to form a blend; compacting, such as roller compacting, said blend; optionally mixing with further pharmaceutically acceptable excipients, and optionally compressing the final blend into a solid oral dosage form.
  • a further embodiment of the present invention is a process for the manufacture of a tablet according to the present invention.
  • the pharmaceutical oral fixed compositions of the invention are tablets of low friability.
  • the friability is not more than 0.8%.
  • the friability is measured by standard methods known to the person skilled in the art, see the harmonized procedure set forth in the pharmacopeias USP ⁇ 1216> and EP 2.9.7 and JP.
  • the pharmaceutical oral fixed compositions of the invention are tablets of suitable hardness (e.g. an average hardness ranging from about 30 N to about 110 N). Such an average hardness is determined prior to the application of any film coating on the pharmaceutical oral fixed dose combinations.
  • a preferred embodiment of this invention is directed to pharmaceutical oral compositions which are film-coated.
  • suitable film coatings are known and commercially available or can be made according to known methods.
  • the film coating material is a polymeric film coating material comprising materials such as hydroxypropylmethyl cellulose or polyvinyl alcohol, polyethylene glycol, lecithin, talc and colorant.
  • a film coating material is applied in such an amount as to provide a film coating that ranges from about 1% to about 6% by weight of the film-coated tablet.
  • a coating comprising polyvinyl alcohol and materials such as polyethylene glycol, talc, and colorants (such as Opadry AMB or Opadry II 85F) can be applied as a moisture barrier to provide additional moisture protection to prevent conversion of the active ingredient to other polymorphic forms.
  • Sufficient moisture protection can also be achieved through various packaging, including but not limited to: heat-induction sealed HDPE bottles with or without desiccant, and blister packaging materials known in the industry to have low moisture vapor permeation rates (i.e. aluminum/aluminum, PVC/PCTFE (polyvinylchloride/polychlorotrifluoroethylene), ACLAR).
  • the invention provides a process for the preparation of pharmaceutical oral compositions as described herein above.
  • Such pharmaceutical oral fixed dose combination may be produced by working up components as defined herein above in the appropriate amounts, to form unit pharmaceutical oral fixed dose combinations.
  • the pharmaceutical compositions are useful in treating or preventing a condition or disorder associated with DGAT1 activity.
  • the conditions for which the instant invention is useful include, without limitation, a metabolic disorder such as obesity, diabetes, anorexia nervosa, bulimia, cachexia, syndrome X, insulin resistance, hypoglycemia, hyperglycemia, hyperuricemia, hyperinsulinemia, hypercholesterolemia, hyperlipidemia, dyslipidemia, mixed dyslipidemia, hypertriglyceridemia, chlomicronemia, familial chylomicronemia, and nonalcoholic fatty liver disease; cardiovascular diseases, such as atherosclerosis, arteriosclerosis, acute heart failure, congestive heart failure, coronary artery disease, cardiomyopathy, myocardial infarction, angina pectoris, hypertension, hypotension, stroke, ischemia, ischemic reperfusion injury, aneurysm, restenosis, and vascular stenosis; neoplastic diseases, such as solid tumors, skin cancer, melanom
  • the present invention thus provides a method for treating or preventing a condition or disorder associated with DGAT1 activity, comprising administering to an animal, including a human patient, in need of such treatment a therapeutically effective amount of the pharmaceutical composition according to the present invention.
  • the present invention likewise provides the use of a pharmaceutical composition according to the present invention for the manufacture of a medicament for treating or preventing a condition or disorder associated with DGAT1 activity.
  • the present invention likewise provides a pharmaceutical composition according to the present invention for use in treating or preventing a condition or disorder associated with DGAT1 activity.
  • the exact dose of the active agent and the particular formulation to be administered depend on a number of factors, e.g., the condition to be treated, the desired duration of the treatment and the rate of release of the active agent.
  • the amount of the active agent required and the release rate thereof may be determined on the basis of known in vitro or in vivo techniques, determining how long a particular active agent concentration in the blood plasma remains at an acceptable level for a therapeutic effect.
  • the tablets of the Examples are tested for their dissolution in 900 ml of pH 6.8 phosphate buffer with paddles at 75 rpm.
  • the assembly consists of the following: a covered vessel made of glass or other inert, transparent material; a motor, and a paddle formed from a blade and shaft as the stirring element.
  • the vessel is partially immersed in a suitable water bath of any convenient size or placed in a heating jacket.
  • the water bath or heating jacket permits holding the temperature inside the vessels at 37 ⁇ 0.5° during the test and keeping the bath fluid in constant, smooth motion.
  • Apparatus that permits observation of the specimen and stirring element during the test is has the following dimensions and capacities: the height is 160 mm to 210 mm and its inside diameter is 98 mm to 106 mm.
  • the shaft is positioned so that its axis is not more than 2 mm at any point from the vertical axis of the vessel and rotates smoothly without significant wobble.
  • the vertical center line of the blade passes through the axis of the shaft so that the bottom of the blade is flush with the bottom of the shaft.
  • the design of the paddle is as shown in USP ⁇ 711>, Fig. 2. The distance of 25 ⁇ 2 mm between the blade and the inside bottom of the vessel is maintained during the test.
  • the metallic or suitably inert, rigid blade and shaft comprise a single entity. A suitable two-part detachable design may be used provided the assembly remains firmly engaged during the test.
  • the paddle blade and shaft may be coated with a suitable inert coating.
  • the dosage unit is allowed to sink to the bottom of the vessel before rotation of the blade is started.
  • a small, loose piece of nonreactive material such as not more than a few turns of wire helix may be attached to dosage units that would otherwise float.
  • Other validated sinker devices may be used.
  • a specimen(> 1 ml) is withdrawn from a zone midway between the surface of the Dissolution Medium and the top of the rotating blade, not less than 1 cm from the vessel wall.
  • a specimen(> 1 ml) is withdrawn from a zone midway between the surface of the Dissolution Medium and the top of the rotating blade, not less than 1 cm from the vessel wall.
  • the vessel is kept covered for the duration of the test, and the temperature of the mixture under test at suitable times is verified.] .
  • the specimen is filtered through a suitable filter, e.g. a 0.45 ⁇ m PVDF filter (Millipore) and the first mls (2 to 3 ml) of the filtrate are discarded.
  • a suitable filter e.g. a 0.45 ⁇ m PVDF filter (Millipore) and the first mls (2 to 3 ml) of the filtrate are discarded.
  • the analysis is performed by HPLC or UV detection.
  • the test is repeated at least 6 times. with additional dosage form units.
  • a Schleuniger 8M Hardness tester was used to perform tablet hardness testing. Tablets were positioned on the instrument stage. Each tablet was oriented in the lengthwise same position according to distinguishing marks (when applicable). Testing was performed for 10 tablets from each batch and each compression force.
  • trans -(4- ⁇ 4-[5-(6-Trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl ⁇ -cyclohexyl)-acetic acid, sodium salt along with Microcrystalline Cellulose (partial), and Crospovidone (intragranular) are mixed in a low shear mixer.
  • the mixed contents, along with remaining Microcrystalline Cellulose are passed through an oscillating mill equipped with a suitable screen.
  • the screened contents are mixed in a low shear mixer for a suitable amount of time.
  • Colloidal silicon dioxide, screened through an appropriate screen is mixed with the blend from earlier step and the contents are mixed for a suitable amount of time.
  • Magnesium Stearate screened through a suitable screen size is added to the preblend and mixed for a suitable amount of time.
  • the lubricated intragranular preblend is passed through a roller compaction system for densification at the optimized parameters for feed rate, roll speed and roll force.
  • the ribbons from the process are collected and passed through an oscillating mill equipped with a suitable screen to get the desired milled material.
  • the milled material is then mixed with extragranular prescreened Crospovidone and mixed in a low shear mixer for a suitable amount of time.
  • prescreened Magnesium Stearate is added and mixed for a suitable amount of time.
  • the final blend is then compressed to the desired tablet weight to achieve the optimized thickness, hardness and disintegration time.
  • Example 1 A Uncoated tablet comprising a DGAT1 inhibitor, (5 ma of active ingredient, based on free acid of Compound 1)
  • Example 1B Uncoated tablet comprising a DGAT1 inhibitor, (10 mg of active ingredient, based on free acid of Compound 1)
  • Example 1.A The Table below shows the dissolution of tablets of Example 1.A which are compressed at two different hardness i.e. 6 kN and 12 kN. The dissolution for the batches was performed using USP-2 Paddle / 0.4% CTAB/ pH 6.8 buffer/ 50 rpm. Table Dissolution summary of Example 1.A (at two hardness levels) Compression hardness % compound of formulat (II) released (% w/w) at the following time points (in minutes) 10 min 20 min 30 min 45 min 60 min 6 kN 65 82 91 101 103 12kN 48 77 82 86 89
  • Microcrystalline cellulose (Avicel), surfactant (sodium lauryl sulfate), disintegrant (Internal), and glidant (Aerosil 200) (Internal) are added to the therapeutic agent.
  • the mixture is sieved and blended prior to lubrication..
  • the lubricant (Internal) is then added to the bin blender and blended for an appropriate amount of time.
  • the mixture is roller compacted using a roller compactor, and then milled.
  • Disintegrant (External), and glidant (Aerosil 200) (External) are added to the mixture and bin blended. Thereafter, the obtained mixture is blended with lubricant (external excipient), sieved in a bin blender.
  • the obtained final mixture is then compressed into a tablet weighing about 100 mg .
  • Example 2A Example 2B Strength 25 mg 25 mg Materials mg/tablet mg/tablet Compound of formula (II) 26.28 26.28 Sodium Lauryl Sulfate - 2 Avicel PH 102 18.22 18.22 Anhydrous Lactose 36 36 Sodium Starch Glycollate (Internal) 3 3 L-HPC LH 21 10 10 Aerosil 200 (Internal) 0.25 0.25 Sodium Stearyl Fumarate (Internal) 0.5 0.5 Sodium Starch Glycollate (External) 3 3 Aerosil 200 (External) 0.25 0.25 Sodium Stearyl Fumarate (External) 0.5 0.5 Total weight (mg) 100 100 Tablet properties Tooling 6 mm round 6 mm round Mean weight (mg) 99.4 100.5 Compression force
  • the dissolution comparison clearly indicates the faster rate of dissolution at the initial two time points for the formulation with 2% w/w of SLS. Moreover, during the processing of the batch containing SLS, it was observed that the sticking tendency to the rolls of the compactor was also significantly reduced. Hence the advantages from the dissolution and processing standpoint made it crucial to include a surfactant with lubricant properties in the formulation.
  • Example 3B The effect of a dry binder with disintegrant properties can be evaluated as follows.
  • Example 3B the non-inclusion of L-HPC LH-21 was compensated by a similar amount of Avicel PH-102 in the external phase.
  • Batch Number Example 3A Example 3B Strength 25 mg 25 mg Materials Mg/tablet Mg/tablet Compound of formula (II) 26.28 26.28 Sodium Lauryl Sulfate 2 2 Avicel PH 102 (Internal) 16.72 16.72 Anhydrous Lactose 36 36 Sodium Starch Glycollate (Internal) 3 3 L-HPC LH 21 10 - Aerosil 200 (Internal) 0.25 0.25 Sodium Stearyl Fumarate (Internal) 1 1 Avicel PH 102 (External) - 10 Sodium Starch Glycollate (External) 3 3 Aerosil 200 (External) 0.25 0.25 Sodium Stearyl Fumarate (External) 1.5 1.5 Total weight (mg) 100 100 Tablet properties
  • a dry binder with lubricant properties is an essential component of the formulations of the present invention.
  • Example 4A Example 4B Strength 25 mg 25 mg Materials mg/tablet mg/tablet Compound of formula (II) 26.28 26.28 Sodium Lauryl Sulfate 2 2 Avicel PH 102 18.22 18.22 Dicalcium Phosphate Anydrous 36 - Anhydrous Lactose - 36 Sodium Starch Glycollate (Internal) 3 3 L-HPC LH 21 10 10 Aerosil 200 (Internal) 0.25 0.25 Sodium Stearyl Fumarate (Internal) 0.5 0.5 Sodium Starch Glycollate (External) 3 3 Aerosil 200 (External) 0.25 0.25 Sodium Stearyl Fumarate (External) 0.5 0.5 Total weight (mg) 100 100 Tablet properties Tooling 6 mm round 6 mm round Compression force (kN) 9.59 4.9 Mean hardness (N) 86.6 64.2 % friability (500 rotations) 0.29% NA Avicel PH 102: Microcrystalline cellulose (MCC) Anhydrous Dicalcium Phos
  • Example 4A and 4B are given in the Table below.
  • the therapeutic agent in these examples is the compound of formula (II).
  • the table below shows the formulation for Examples 5A, 5B and 5C having 25 mg of therapeutic agent-the 25 mg refers to the amount of the compound of formula (I).
  • Examples 5A, 5B and 5C provide possible embodiments of a tablet dosage form using various disintegrants.
  • Microcrystalline cellulose (Avicel). sodium lauryl sulfate, disintegrant (Internal), and Aerosil 200 (Internal) are added to the therapeutic agent. The mixture is sieved and blended prior to lubrication.. The Sodium Stearyl Fumarate (Internal), is then added to the bin blender and blended for an appropriate amount of time. The mixture is roller compacted using a roller compactor, and then milled. Disintegrant (External), and Aerosil 200 (External) are added to the mixture and bin blended. Thereafter, the obtained mixture is blended with Sodium Stearyl Fumarate (external excipient), sieved in a bin blender. The obtained final mixture is then compressed into a tablet weighing about 100 mg .
  • a most preferred disintegrant is sodium starch glycollate, which also gives a good friability level.
  • the therapeutic agent in these examples is the compound of formula (II).
  • the table below shows the formulation for Examples 6.1 to 6.4 having 25 mg of therapeutic agent-the 25 mg refers to the amount of the compound of formula (I). Tablets for examples 6.1 to 6.4 were made by the same process as described in example 2.
  • the dissolution profiles show a clear rank order in terms of level of disintegrant and the rate of dissolution up to 6% level. There was no significant difference in the release rates between 6% and 9%. Greater than 90% of the therapeutic agent is released from Examples with a disintegrant. Disintegrants usually decrease the compressibility of the formulation and higher levels will lead to decreased tablet hardness and/or friability problems. Thus, a fine balance must be struck between the amount of disintegrant and other properties of the formulation.
  • the disintegrant is distributed equally between the the internal and external components. E.g. 6% is distributed as 3% internal and 3% external components, respectively, and 2% is distributed as 1% internal and 1% external components, respectively
  • the therapeutic agent in this example is the compound of formula (II). Tables below show the formulation for Example 7 having 2 mg of therapeutic agent; the 2 mg refers to the amount of the compound of formula (I).
  • Strength 2 mg Materials mg/tablet Therapeutic agent 2.10 Sodium Lauryl Sulfate 2 Avicel PH 102 (Internal) 25.63 Anhydrous Lactose DT 51.27 Sodium Starch Glycollate (Internal) 3 L-HPC LH 21 10 Aerosil 200 (Internal) 0.25 Sodium Stearyl Fumarate (Internal) 1 Sodium Starch Glycollate (External) 3 Aerosil 200 (External) 0.25 Sodium Stearyl Fumarate (External) 1.5 Total weight (mg) 100 Tablet properties Tooling 6 mm standard round Compression force (kN) 8.0 Mean hardness (N) 34.0 % friability (500 rotations) 0.66 (6 KN, 23.6 N hardness) DT mins (with disc.) 4.8
  • Example 8 20 mg Strength uncoated tablets with 6% disintegrant, and 2% disintegrant
  • the therapeutic agent in these examples is the compound of formula (II).
  • Table below shows the formulation for Examples 8.1 and 8.2 having 20 mg of therapeutic agent-the 20 mg refers to the amount of the compound of formula (I).
  • Batch Number Example 8.1 Example 8.2 Strength 20 mg 20 mg Materials mg/tablet mg/tablet Therapeutic agent 21.02 21.02 Sodium Lauryl Sulfate 2 2 Avicel PH 102 19.33 20.67 Anhydrous Lactose 38.67 41.33 Sodium Starch Glycollate (Internal) 3 1 L-HPC LH 21 10 10 Aerosil 200 (Internal) 0.25 0.25 Sodium Stearyl Fumarate (Internal) 1.0 1.0 Sodium Starch Glycollate (External) 3 1 Aerosil 200 (External) 0.25 0.25 Sodium Stearyl Fumarate (External) 1.5 1.5 Total weight (mg) 100 100
  • Example 10 Bioavailability of tablet formulations.
  • a single center, randomized, open-label, single dose, parallel-group study is carried out to assess the relative bioavailability of the therapeutic agent following oral administration of a single dose of the compound of formula (II) as tablet (20 mg) formulations administered to healthy subjects under fasting or fed conditions (standard FDA breakfast).
  • a total of 120 subjects are enrolled and equally distributed to 5 treatment arms (24 subjects/treatment arm, in a 1:1:1:1:1 ratio).
  • PK pharmacokinetic
  • Safety assessments include physical examinations, ECGs, vital signs, standard clinical laboratory evaluations hematology, blood chemistry, urinalysis, adverse event and serious adverse event monitoring.
  • Examples 8.1 and 8.2 are thus similar to Reference Example 1.B in terms of the rate and extent of absorption of the therapeutic agent.
  • the invention thus provides a pharmaceutical composition of the compound of formula (I), or a pharmaceutically acceptable salt thereof, which exhibits one or more, e.g. 1, 2 or 3, of the following desirable characteristics;
  • the formulations of the present invention are also achievable via a robust manufacturing process; which gives good flowability, compactibility, and which minimizes sticking problems and capping of tabletting mixtures on the rotary press.
  • the process and the formulations are amenable to scale-up, with a reproducible performance.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Claims (15)

  1. Composition pharmaceutique sous la forme d'un comprimé avec un pelliculage facultatif comprenant
    a) une quantité thérapeutiquement efficace du sel de sodium du composé acide trans-(4-{4-[5-(6-trifluorométhyl-pyridin-3-ylamino)-pyridin-2-yl]-phényl}-cyclohexyl)-acétique de formule (I),
    Figure imgb0008
    b) du laurylsulfate de sodium en tant que tensioactif ayant des propriétés lubrifiantes,
    dans laquelle ledit tensioactif est présent en une quantité qui est de 0,1 à 5 % en poids du comprimé avant un pelliculage facultatif et sur la base de l'acide libre du composé de formule (I) ;
    c) de l'hydroxypropylméthylcellulose ou de l'hydroxypropylcellulose, toutes deux de viscosité moyenne à élevée, et des combinaisons de celles-ci en tant que liant sec,
    dans laquelle ledit liant sec est présent en une quantité qui est de 2 à 20 % en poids du comprimé avant un pelliculage facultatif et sur la base de l'acide libre du composé de formule (I) ;
    d) une charge choisie parmi la cellulose microcristalline, le phosphate dicalcique anhydre, le lactose anhydre, et des mélanges de ceux-ci, et une combinaison de cellulose microcristalline et de phosphate dicalcique anhydre, et une combinaison de cellulose microcristalline et de lactose, et
    dans laquelle ladite charge est présente en une quantité qui est de 4 % à 85 % en poids du comprimé avant un pelliculage facultatif et sur la base de l'acide libre du composé de formule (I), et
    e) du glycolate d'amidon sodique en tant que délitant,
    dans laquelle ledit délitant est présent en une quantité qui est 1 à 10 % en poids du comprimé avant un pelliculage facultatif et sur la base de l'acide libre du composé de formule (I).
  2. Composition pharmaceutique selon la revendication 1, dans laquelle la charge est présente en une quantité qui est de 20 % à 85 %, de préférence 50 % à 80 %, en poids du comprimé avant un pelliculage facultatif et sur la base de l'acide libre du composé de formule (I).
  3. Composition pharmaceutique selon la revendication 1 ou 2, comprenant en outre un lubrifiant, dans laquelle le lubrifiant est choisi parmi le stéarylfumarate de sodium et le stéarate de magnésium, et
    dans laquelle le lubrifiant est présent en une quantité qui est de 0,1 % à 10 %, de préférence de 0,5 % à 5 % en poids du comprimé avant un pelliculage facultatif et sur la base de l'acide libre du composé de formule (I).
  4. Composition pharmaceutique selon la revendication 3, dans laquelle le lubrifiant est le stéarylfumarate de sodium.
  5. Composition pharmaceutique selon l'une quelconque des revendications précédentes comprenant en outre un agent glissant, dans laquelle l'agent glissant est choisi parmi du dioxyde de silicium colloïdal, du trisilicate de magnésium, de la cellulose pulvérulente, de l'amidon, du talc et des combinaisons de ceux-ci, et dans laquelle l'agent glissant est présent en une quantité dans la plage d'environ 0,05 % à environ 5 %, de préférence d'environ 0,1 % à environ 1 %, plus préférablement d'environ 0,25 % à environ 1 %, en poids du comprimé avant un pelliculage facultatif et sur la base de l'acide libre du composé de formule (I).
  6. Composition pharmaceutique selon l'une quelconque des revendications précédentes, dans laquelle l'hydroxypropylméthylcellulose ou l'hydroxypropylcellulose en tant que liant sec sont toutes deux de grades de viscosité de 3 ou 6 cps, de manière préférée entre toutes une hydroxypropylcellulose faiblement substituée (L-HPC LH-21) ; et des combinaisons de celles-ci.
  7. Composition pharmaceutique selon l'une quelconque des revendications précédentes, dans laquelle le liant sec est présent en une quantité qui est de 5 à 15 % en poids du comprimé avant un pelliculage facultatif et sur la base de l'acide libre du composé de formule (I).
  8. Composition pharmaceutique selon l'une quelconque des revendications précédentes, dans laquelle la charge est une combinaison de cellulose microcristalline et de phosphate dicalcique anhydre, ou une combinaison de cellulose microcristalline et de lactose dans laquelle le rapport des composants de charge est compris entre 1:5 et 1:1, de préférence 1:2.
  9. Composition pharmaceutique selon l'une quelconque des revendications précédentes, dans laquelle le délitant est présent en une quantité qui est de 2, 6 ou 9 % en poids du comprimé avant un pelliculage facultatif et sur la base de l'acide libre du composé de formule (I).
  10. Composition pharmaceutique selon l'une quelconque des revendications précédentes, dans laquelle le composé de formule (I) est présent en une quantité dans la plage d'environ 0,1 % à environ 50 %, de préférence d'environ 0,5 % à environ 30 %, de manière préférée entre toutes d'environ 1 à 30 %, en poids du comprimé avant un pelliculage facultatif et sur la base de l'acide libre du composé de formule (I).
  11. Composition pharmaceutique selon l'une quelconque des revendications précédentes, dans laquelle
    le tensioactif est le laurylsulfate de sodium ;
    le liant sec est de l'hydroxypropylcellulose faiblement substituée (L-HPC LH-21) ;
    la charge est un mélange de cellulose microcristalline et de lactose dans lequel le rapport de la cellulose microcristalline et du lactose est compris entre 1:5 et 1:1, de préférence 1:2, et le délitant est le glycolate d'amidon sodique.
  12. Composition pharmaceutique selon la revendication 11, comprenant en outre le lubrifiant stéarylfumarate de sodium.
  13. Composition pharmaceutique selon l'une quelconque des revendications 1 à 12 sous la forme d'un comprimé pelliculé, où le matériau de pelliculage est un matériau de pelliculage polymère comprenant de l'hydroxypropylméthylcellulose ou de l'alcool polyvinylique, du polyéthylène glycol, de la lécithine, du talc et du colorant.
  14. Composition pharmaceutique selon l'une quelconque des revendications précédentes 1 à 13 pour utilisation dans le traitement ou la prévention d'une affection ou d'un trouble associé à l'activité DGAT1.
  15. Procédé de préparation d'une composition pharmaceutique selon l'une quelconque des revendications précédentes 1 à 12, comprenant les étapes de :
    a) mélange du sel de sodium du composé acide trans-(4-{4-[5-(6-trifluorométhyl-pyridin-3-ylamino)-pyridin-2-yl]-phényl}-cyclohexyl)-acétique de formule (I), avec au moins un excipient pharmaceutiquement acceptable pour former un mélange ;
    b) compactage au rouleau, puis broyage dudit mélange ;
    c) lubrification du mélange résultant, et
    d) compression du mélange résultant en forme pharmaceutique orale solide.
EP11779278.8A 2010-10-14 2011-10-14 Compositions pharmaceutiques contenant un inhibiteur dgat1 Active EP2627319B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL11779278T PL2627319T3 (pl) 2010-10-14 2011-10-14 Kompozycje farmaceutyczne zawierające inhibitor DGAT1
SI201131677T SI2627319T1 (sl) 2010-10-14 2011-10-14 Farmacevtski sestavki, ki vsebujejo inhibitor DGAT1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39310310P 2010-10-14 2010-10-14
PCT/US2011/056275 WO2012051488A1 (fr) 2010-10-14 2011-10-14 Compositions pharmaceutiques contenant un inhibiteur dgat1

Publications (2)

Publication Number Publication Date
EP2627319A1 EP2627319A1 (fr) 2013-08-21
EP2627319B1 true EP2627319B1 (fr) 2018-11-21

Family

ID=44908106

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11779278.8A Active EP2627319B1 (fr) 2010-10-14 2011-10-14 Compositions pharmaceutiques contenant un inhibiteur dgat1

Country Status (29)

Country Link
US (5) US20130190354A1 (fr)
EP (1) EP2627319B1 (fr)
JP (1) JP6060081B2 (fr)
KR (1) KR20130100311A (fr)
CN (1) CN103179957B (fr)
AR (1) AR083417A1 (fr)
AU (1) AU2011316003B2 (fr)
BR (1) BR112013008757A2 (fr)
CA (1) CA2813781C (fr)
CL (1) CL2013001001A1 (fr)
CO (1) CO6710915A2 (fr)
DK (1) DK2627319T3 (fr)
EC (1) ECSP13012755A (fr)
ES (1) ES2712064T3 (fr)
GT (1) GT201300096A (fr)
HU (1) HUE043524T2 (fr)
IL (1) IL225434A0 (fr)
MA (1) MA34599B1 (fr)
MX (1) MX2013004162A (fr)
NZ (1) NZ608558A (fr)
PE (1) PE20140375A1 (fr)
PL (1) PL2627319T3 (fr)
PT (1) PT2627319T (fr)
RU (1) RU2595866C2 (fr)
SG (1) SG189078A1 (fr)
SI (1) SI2627319T1 (fr)
TR (1) TR201902435T4 (fr)
WO (1) WO2012051488A1 (fr)
ZA (1) ZA201302108B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013055910A1 (fr) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés
US9108956B2 (en) * 2012-04-27 2015-08-18 Novartis Ag Cyclic ether DGAT1 inhibitorscyclic ether DGAT1 inhibitors
WO2013169648A1 (fr) * 2012-05-07 2013-11-14 Novartis Ag Combinaisons pharmaceutiques comprenant un inhibiteur de dgat1 et un médicament abaissant la teneur en triglycérides
WO2014074668A1 (fr) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
CN107530307A (zh) 2015-03-13 2018-01-02 艾斯柏伦治疗公司 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
EP3391881A4 (fr) * 2015-11-19 2020-03-11 Sinew Pharma Inc. Composition pharmaceutique destinée à prévenir et traiter la stéatose hépatique
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
AU2017226389B2 (en) 2016-03-04 2023-02-02 Taiho Pharmaceutical Co., Ltd. Preparation and composition for treatment of malignant tumors
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
US10632092B2 (en) 2017-08-30 2020-04-28 First Fruits Business Ministry, Llc Composition for and method to increase serum adiponectin and reduce body fat
KR20200136428A (ko) 2018-03-16 2020-12-07 앤지 파마수티컬스 잉크. 심한 변비를 치료하기 위한 조성물 및 방법
PL3769765T3 (pl) * 2018-03-19 2024-06-10 Taiho Pharmaceutical Co., Ltd. Kompozycja farmaceutyczna zawierająca alkilosiarczan sodu

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123401A1 (fr) * 2010-03-30 2011-10-06 Novartis Ag Utilisations d'inhibiteurs de dgat1

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2224184T3 (es) 1995-11-14 2005-03-01 ABBOTT GMBH & CO. KG Preparaciones estabilizadas de hormonas tiroideas y metodos para su fabricacion.
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
DE19816070A1 (de) * 1998-04-09 1999-10-14 Aventis Res & Tech Gmbh & Co Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden
JP2005513099A (ja) * 2001-12-21 2005-05-12 ファイザー・プロダクツ・インク アジスロマイシンの直接的に圧縮可能な配合品
MX2007013049A (es) * 2005-04-19 2008-01-11 Bayer Pharmaceuticals Corp Preparacion y uso de derivados de aril alquil acido para el tratamiento de la obesidad.
KR101219042B1 (ko) * 2005-12-06 2013-01-07 삼성디스플레이 주식회사 반투과형 액정 표시 장치
CN101365432B (zh) * 2005-12-16 2011-06-22 默沙东公司 二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物
AU2007223278A1 (en) 2006-03-06 2007-09-13 Wyeth Tablet formulations and processes
US20070224258A1 (en) * 2006-03-22 2007-09-27 Bunick Frank J Dosage forms having a randomized coating
EP2004607B1 (fr) * 2006-03-31 2011-10-19 Novartis AG Dérivés de l'acide (4-(4-[6-(trifluorométhyl-pyridin-3-ylamino)-N-contenant-hétéroaryl]-phényl)-cyclohexyl)-acétique et leurs applications pharmaceutiques
AU2007325350B2 (en) 2006-11-29 2012-09-20 Abbvie Inc. Inhibitors of diacylglycerol O-acylotransferase type 1 enzyme
US20080145425A1 (en) * 2006-12-15 2008-06-19 Pliva Research & Development Limited Pharmaceutical composition of zolpidem
CN101743234A (zh) 2007-04-30 2010-06-16 雅培制药有限公司 二酰甘油o-酰基转移酶1型酶的抑制剂
WO2009048932A2 (fr) * 2007-10-09 2009-04-16 Children's Medical Center Corporation Procédés pour réguler le traitement d'un arnmi par ciblage de la protéine lin-28
JP2012522058A (ja) * 2009-03-31 2012-09-20 リガンド・ファーマシューティカルズ・インコーポレイテッド 血圧上昇および糖尿病性腎症を処置するための、ジフェニルスルホンアミドエンドセリンおよびアンジオテンシンｉｉ受容体アゴニストの経口製剤
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123401A1 (fr) * 2010-03-30 2011-10-06 Novartis Ag Utilisations d'inhibiteurs de dgat1

Also Published As

Publication number Publication date
JP2013539794A (ja) 2013-10-28
KR20130100311A (ko) 2013-09-10
US20160374947A1 (en) 2016-12-29
MA34599B1 (fr) 2013-10-02
PL2627319T3 (pl) 2019-05-31
US20200230062A1 (en) 2020-07-23
US11304907B2 (en) 2022-04-19
DK2627319T3 (en) 2019-03-18
CN103179957A (zh) 2013-06-26
AU2011316003B2 (en) 2015-03-19
CA2813781C (fr) 2018-08-07
CO6710915A2 (es) 2013-07-15
EP2627319A1 (fr) 2013-08-21
US20130190354A1 (en) 2013-07-25
IL225434A0 (en) 2013-06-27
PE20140375A1 (es) 2014-03-19
NZ608558A (en) 2015-03-27
CA2813781A1 (fr) 2012-04-19
CN103179957B (zh) 2016-05-18
GT201300096A (es) 2014-07-08
AU2011316003A1 (en) 2013-04-11
RU2595866C2 (ru) 2016-08-27
SG189078A1 (en) 2013-05-31
WO2012051488A1 (fr) 2012-04-19
HUE043524T2 (hu) 2019-08-28
MX2013004162A (es) 2014-12-08
ECSP13012755A (es) 2014-01-31
ES2712064T3 (es) 2019-05-09
JP6060081B2 (ja) 2017-01-11
US20180243222A1 (en) 2018-08-30
CL2013001001A1 (es) 2013-10-25
RU2013121795A (ru) 2014-11-20
ZA201302108B (en) 2013-11-27
AR083417A1 (es) 2013-02-21
PT2627319T (pt) 2019-02-27
US10646446B2 (en) 2020-05-12
SI2627319T1 (sl) 2019-04-30
US20150320687A1 (en) 2015-11-12
BR112013008757A2 (pt) 2020-09-01
TR201902435T4 (tr) 2019-03-21

Similar Documents

Publication Publication Date Title
US11304907B2 (en) Pharmaceutical compositions containing a DGAT1 inhibitor
TWI778983B (zh) 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
RU2493844C2 (ru) Фармацевтические композиции двойного действия на основе надмолекулярных структур антагониста/блокатора рецепторов ангиотензина (arb) и ингибитора нейтральной эндопептидазы (nep)
KR101641517B1 (ko) Ｂｉｂｗ 2992를 포함하는 약제학적 고체 제형
CA2501659C (fr) Comprimes solubles de deferasirox
EA034243B1 (ru) Фармацевтические композиции, содержащие azd9291, для лечения рака
TW201336491A (zh) 含菲索特羅定之安定化醫藥組成物
WO2004054574A1 (fr) Medicament solide administre par voie orale
EP2514422B1 (fr) Préparation du teneligliptine à élution stabilisée
EP2635263B1 (fr) Composition avec s-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate et sodium croscarmellose
US8613949B2 (en) Galenical formulations of organic compounds
JP6328138B2 (ja) Ｎ−［５−［２−（３，５−ジメトキシフェニル）エチル］−２ｈ−ピラゾール−３−イル］−４−［（３ｒ，５ｓ）−３，５−ジメチルピペラジン−１−イル］ベンズアミドの医薬製剤
KR100700472B1 (ko) 프로펜 함유 제약 혼합물
EP3072529B1 (fr) Composition comprenant du vemurafenib et du hpmc-as
EP3939589A1 (fr) Comprimé à charge de médicament élevée comprenant du voxélotor
TW202200122A (zh) 二氟甲基鳥氨酸及舒林酸（ｓｕｌｉｎｄａｃ），固定劑量組合調配物
EP2543362A1 (fr) Forme pharmaceutique solide orale à libération prolongée de dronédarone ou l'un de ses sels pharmaceutiquement acceptables
SHANNON et al. Patent 3003149 Summary

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130514

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1184062

Country of ref document: HK

17Q First examination report despatched

Effective date: 20150720

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/28 20060101ALI20180329BHEP

Ipc: A61K 31/444 20060101ALI20180329BHEP

Ipc: A61K 47/20 20060101ALI20180329BHEP

Ipc: A61K 47/38 20060101ALI20180329BHEP

Ipc: A61K 9/20 20060101AFI20180329BHEP

Ipc: A61K 47/26 20060101ALI20180329BHEP

INTG Intention to grant announced

Effective date: 20180430

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAL Information related to payment of fee for publishing/printing deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

INTG Intention to grant announced

Effective date: 20181004

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011054110

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1066720

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181215

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2627319

Country of ref document: PT

Date of ref document: 20190227

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20190221

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20190311

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181121

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181121

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181121

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190321

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2712064

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20190509

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20181121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181121

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181121

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 30187

Country of ref document: SK

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20190400603

Country of ref document: GR

Effective date: 20190509

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011054110

Country of ref document: DE

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E043524

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181121

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181121

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20190822

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191014

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1066720

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181121

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230514

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20230912

Year of fee payment: 13

Ref country code: IT

Payment date: 20230913

Year of fee payment: 13

Ref country code: CZ

Payment date: 20230919

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20230912

Year of fee payment: 13

Ref country code: SE

Payment date: 20230830

Year of fee payment: 13

Ref country code: PL

Payment date: 20230821

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231103

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20231012

Year of fee payment: 13

Ref country code: SI

Payment date: 20230825

Year of fee payment: 13

Ref country code: PT

Payment date: 20231011

Year of fee payment: 13

Ref country code: NO

Payment date: 20231010

Year of fee payment: 13

Ref country code: HU

Payment date: 20230901

Year of fee payment: 13

Ref country code: FI

Payment date: 20231011

Year of fee payment: 13

Ref country code: DK

Payment date: 20231016

Year of fee payment: 13

Ref country code: DE

Payment date: 20230822

Year of fee payment: 13

Ref country code: CH

Payment date: 20231102

Year of fee payment: 13

Ref country code: AT

Payment date: 20230925

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240826

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20240829

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240823

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240912

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240822

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20240917

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240821

Year of fee payment: 14